Journal Mobile Options
Table of Contents
Vol. 62, No. 1, 2010
Issue release date: June 2010
Neuropsychobiology 2010;62:17–26

The New Lithium Clinic

Osher Y. · Bersudsky Y. · Belmaker R.H.
Beer Sheva Mental Health Center, Ministry of Health and Ben Gurion University of the Negev, Beer Sheva, Israel

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Until the early 1950s, no effective pharmacological treatment existed for bipolar affective disorder. By the early 1960s, specialty clinics were being set up to dispense lithium carbonate to bipolar patients. By the late 1980s, a new body of knowledge was influencing the perception of bipolar disorder and how the disease should be treated. The authors’ lithium clinic from 1974 has grown and evolved from a lithium blood level monitoring model into a comprehensive care model with polypharmacy, psychoeducation, rehabilitation, cognitive therapy, social rhythm therapy, and employment counseling as well as a staff of 2 part-time psychiatrists and 1 clinical psychologist. This service delivery model may benefit both treatment and research in bipolar disorder. The evolution of psychopharmacological and psychosocial knowledge in treating bipolar illness has been integrated into our clinic. Case vignettes are presented to illustrate these points. The comparative cost of this model is discussed.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Schou M: Lithium in psychiatric therapy. Stock-taking after ten years. Psychopharmacologia 1959;1:65–78.
  2. Fieve RR: The lithium clinic: a new model for the delivery of psychiatric services. Am J Psychiatry 1975;132:1018–1022.
  3. Kerry RJ: A special lithium clinic. Dis Nerv Syst 1969;30:490–492.
  4. Bey DR, Chapman RE, Tornquist KL: A lithium clinic. Am J Psychiatry 1972;129:468–470.
  5. Ellenberg J, Salamon I, Meaney C: A lithium clinic in a community mental health center. Hosp Community Psychiatry 1980;31:834–836.
  6. Schweitzer I, Davies B, Burrows G, Branton L, Turecek LR, Tiller J: The Royal Melbourne Hospital Lithium Clinic. Aust NZ J Psychiatry 1999;(33 Suppl):S35–S38.
  7. Pietzcker A, Muller-Oerlinghausen B: The outpatient clinic for patients under chronic lithium or neuroleptic treatment as a phase-IV research tool. Pharmacopsychiatry 1984;17:162–167.
  8. Coombs HI, Coombs RRH, Mee UG: Flame photometry; in Johnson FN (ed): Lithium Research and Therapy. London, Academic Press Inc, 1975, pp 167–172.
  9. Cousins DA, Young AH: The armamentarium of treatments for bipolar disorder: a review of the literature. Int J Neuropsychopharmacol 2007;10:411–431.
  10. Fountoulakis KN, Vieta E: Treatment of bipolar disorder: a systematic review of available data and clinical perspectives. Int J Neuropsychopharmacol 2008;11:999–1029.
  11. Frye MA, Ketter TA, Leverich GS, Huggins T, Lantz C, Denicoff KD, Post RM: The increasing use of polypharmacotherapy for refractory mood disorders: 22 years of study. J Clin Psychiatry 2000;61:9–15.
  12. Okuma T, Inanaga K, Otsuki S, Sarai K, Takahashi R, Hazama H, Mori A, Watanabe S: A preliminary double-blind study on the efficacy of carbamazepine in prophylaxis of manic-depressive illness. Psychopharmacology (Berl) 1981;73:95–96.
  13. Post RM, Weiss SRB, Clark M, Chuang D-M, Hough C, Li H: Lithium, carbamazapine, and valproate in affective illness; in Manji HK, Bowden CL, Belmaker RH (eds): Bipolar Medications: Mechanisms of Action. Washington, American Psychiatric Press, Inc, 2000, pp 219–248.
  14. Klein E, Bental E, Lerer B, Belmaker RH: Carbamazepine and haloperidol vs placebo and haloperidol in excited psychoses. A controlled study. Arch Gen Psychiatry 1984;41:165–170.
  15. Emrich HM, von Zerssen D, Kissling W, Moller HJ: Therapeutic effect of valproate in mania. Am J Psychiatry 1981;138:256.
  16. Bowden CL, Brugger AM, Swann AC, Calabrese JR, Janicak PG, Petty F, Dilsaver SC, Davis JM, Rush AJ, Small JG, et al: Efficacy of divalproex vs lithium and placebo in the treatment of mania. The Depakote Mania Study Group. JAMA 1994;271:918–924.
  17. Bowden CL, Calabrese JR, Sachs G, Yatham LN, Asghar SA, Hompland M, Montgomery P, Earl N, Smoot TM, DeVeaugh-Geiss J: A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry 2003;60:392–400.
  18. Levine J, Bersudsky Y, Nadri C, Yaroslavsky Y, Abed N, Mishory A, Agam G, Belmaker RH: Mechanism of action of new mood stabilizing drugs; in Soares JC, Gershon S (eds): Handbook of Medical Psychiatry. New York, Dekker, 2003, pp 793–806.
  19. Prica C, Hascoet M, Bourin M: Antidepressant-like effect of lamotrigine is reversed by veratrine: a possible role of sodium channels in bipolar depression. Behav Brain Res 2008;191:49–54.
  20. Mishory A, Winokur M, Bersudsky Y: Prophylactic effect of phenytoin in bipolar disorder: a controlled study. Bipolar Disord 2003;5:464–467.
  21. Yatham LN, Kennedy SH, Schaffer A, Parikh SV, Beaulieu S, O’Donovan C, MacQueen G, McIntyre RS, Sharma V, Ravindran A, Young LT, Young AH, Alda M, Milev R, Vieta E, Calabrese JR, Berk M, Ha K, Kapczinski F: Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disord 2009;11:225–255.
  22. Ahlfors UG, Baastrup PC, Dencker SJ, Elgen K, Lingjaerde O, Pedersen V, Schou M, Aaskoven O: Flupenthixol decanoate in recurrent manic-depressive illness. A comparison with lithium. Acta Psychiatr Scand 1981;64:226–237.
  23. Bond DJ, Pratoomsri W, Yatham LN: Depot antipsychotic medications in bipolar disorder: a review of the literature. Acta Psychiatr Scand Suppl 2007;434:3–16.
  24. Littlejohn R, Leslie F, Cookson J: Depot antipsychotics in the prophylaxis of bipolar affective disorder. Br J Psychiatry 1994;165:827–829.
  25. Tohen M, Zhang F, Taylor CC, Burns P, Zarate C, Sanger T, Tollefson G: A meta-analysis of the use of typical antipsychotic agents in bipolar disorder. J Affect Disord 2001;65:85–93.
  26. Biederman J, Lerner Y, Belmaker RH: Combination of lithium carbonate and haloperidol in schizo-affective disorder: a controlled study. Arch Gen Psychiatry 1979;36:327–333.
  27. Fink M, Klein DF, Kramer JC: Clinical efficacy of chlorpromazine-procyclidine combination, imipramine and placebo in depressive disorders. Psychopharmacologia 1965;7:27–36.
  28. Osher Y, Yaroslavsky Y, el-Rom R, Belmaker RH: Predominant polarity of bipolar patients in Israel. World J Biol Psychiatry 2000;1:187–189.
  29. Sachs GS, Nierenberg AA, Calabrese JR, Marangell LB, Wisniewski SR, Gyulai L, Friedman ES, Bowden CL, Fossey MD, Ostacher MJ, Ketter TA, Patel J, Hauser P, Rapport D, Martinez JM, Allen MH, Miklowitz DJ, Otto MW, Dennehy EB, Thase ME: Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med 2007;356:1711–1722.
  30. Belmaker RH: Bipolar disorder. N Engl J Med 2004;351:476–486.
  31. Gijsman HJ, Geddes JR, Rendell JM, Nolen WA, Goodwin GM: Antidepressants for bipolar depression: a systematic review of randomized, controlled trials. Am J Psychiatry 2004;161:1537–1547.
  32. Nemets B, Stahl Z, Belmaker RH: Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder. Am J Psychiatry 2002;159:477–479.
  33. Coppen A, Bolander-Gouaille C: Treatment of depression: time to consider folic acid and vitamin B12. J Psychopharmacol 2005;19:59–65.
  34. Mead GE, Morley W, Campbell P, Greig CA, McMurdo M, Lawlor DA: Exercise for depression. Cochrane Database Syst Rev 2008;4:CD004366.
  35. Morgan AJ, Jorm AF: Self-help interventions for depressive disorders and depressive symptoms: a systematic review. Ann Gen Psychiatry 2008;7:13.
  36. Miklowitz DJ: Adjunctive psychotherapy for bipolar disorder: state of the evidence. Am J Psychiatry 2008;165:1408–1419.
  37. Angst J: Clinical typology of bipolar illness; in Belmaker RH, van Praag HM (eds): Mania: An Evolving Concept. New York, Spectrum Publications, Inc, 1980, pp 61–76.
  38. Prien RF, Kupfer DJ, Mansky PA, Small JG, Tuason VB, Voss CB, Johnson WE: Drug therapy in the prevention of recurrences in unipolar and bipolar affective disorders. Report of the NIMH Collaborative Study Group comparing lithium carbonate, imipramine, and a lithium carbonate-imipramine combination. Arch Gen Psychiatry 1984;41:1096–1104.
  39. Mishory A, Yaroslavsky Y, Bersudsky Y, Belmaker RH: Phenytoin as an antimanic anticonvulsant: a controlled study. Am J Psychiatry 2000;157:463–465.
  40. Judd LL, Akiskal HS, Schettler PJ, Endicott J, Maser J, Solomon DA, Leon AC, Rice JA, Keller MB: The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry 2002;59:530–537.
  41. Judd LL, Schettler PJ, Solomon DA, Maser JD, Coryell W, Endicott J, Akiskal HS: Psychosocial disability and work role function compared across the long-term course of bipolar I, bipolar II and unipolar major depressive disorders. J Affect Disord 2008;108:49–58.
  42. Huxley N, Baldessarini RJ: Disability and its treatment in bipolar disorder patients. Bipolar Disord 2007;9:183–196.
  43. Brieger P, Bloink R, Rottig S, Marneros A: Disability payments due to unipolar depressive and bipolar affective disorders. Psychiatr Prax 2004;31:203–206.
  44. Kogan JN, Otto MW, Bauer MS, Dennehy EB, Miklowitz DJ, Zhang HW, Ketter T, Rudorfer MV, Wisniewski SR, Thase ME, Calabrese J, Sachs GS: Demographic and diagnostic characteristics of the first 1,000 patients enrolled in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Bipolar Disord 2004;6:460–469.
  45. Judd LL, Akiskal HS, Schettler PJ, Endicott J, Leon AC, Solomon DA, Coryell W, Maser JD, Keller MB: Psychosocial disability in the course of bipolar I and II disorders: a prospective, comparative, longitudinal study. Arch Gen Psychiatry 2005;62:1322–1330.
  46. Suppes T, Leverich GS, Keck PE, Nolen WA, Denicoff KD, Altshuler LL, McElroy SL, Rush AJ, Kupka R, Frye MA, Bickel M, Post RM: The Stanley Foundation Bipolar Treatment Outcome Network. 2. Demographics and illness characteristics of the first 261 patients. J Affect Disord 2001;67:45–59.
  47. Savitz J, Solms M, Ramesar R: Neuropsychological dysfunction in bipolar affective disorder: a critical opinion. Bipolar Disord 2005;7:216–235.
  48. Mur M, Portella MJ, Martinez-Aran A, Pifarre J, Vieta E: Long-term stability of cognitive impairment in bipolar disorder: a 2-year follow-up study of lithium-treated euthymic bipolar patients. J Clin Psychiatry 2008;69:712–719.
  49. Goodwin GM, Martinez-Aran A, Glahn DC, Vieta E: Cognitive impairment in bipolar disorder: neurodevelopment or neurodegeneration? An ECNP expert meeting report. Eur Neuropsychopharmacol 2008;18:787–793.
  50. Torres IJ, Boudreau VG, Yatham LN: Neuropsychological functioning in euthymic bipolar disorder: a meta-analysis. Acta Psychiatr Scand Suppl 2007;434:17–26.
  51. Martinez-Aran A, Vieta E, Torrent C, Sanchez-Moreno J, Goikolea JM, Salamero M, Malhi GS, Gonzalez-Pinto A, Daban C, Alvarez-Grandi S, Fountoulakis K, Kaprinis G, Tabares-Seisdedos R, Ayuso-Mateos JL: Functional outcome in bipolar disorder: the role of clinical and cognitive factors. Bipolar Disord 2007;9:103–113.
  52. Dickerson FB, Boronow JJ, Stallings CR, Origoni AE, Cole S, Yolken RH: Association between cognitive functioning and employment status of persons with bipolar disorder. Psychiatr Serv 2004;55:54–58.
  53. Solomon DA, Ristow WR, Keller MB, Kane JM, Gelenberg AJ, Rosenbaum JF, Warshaw MG: Serum lithium levels and psychosocial function in patients with bipolar I disorder. Am J Psychiatry 1996;153:1301–1307.
  54. Soares JC, Gershon S: The lithium ion: a foundation for psychopharmacological specificity. Neuropsychopharmacology 1998;19:167–182.
  55. Beynon S, Soares-Weiser K, Woolacott N, Duffy S, Geddes JR: Psychosocial interventions for the prevention of relapse in bipolar disorder: systematic review of controlled trials. Br J Psychiatry 2008;192:5–11.
  56. Vaughn CE, Leff JP: The influence of family and social factors on the course of psychiatric illness. A comparison of schizophrenic and depressed neurotic patients. Br J Psychiatry 1976;129:125–137.
  57. Leff J, Vaughn C: The interaction of life events and relatives’ expressed emotion in schizophrenia and depressive neurosis. Br J Psychiatry 1980;136:146–153.
  58. Morris CD, Miklowitz DJ, Waxmonsky JA: Family-focused treatment for bipolar disorder in adults and youth. J Clin Psychol 2007;63:433–445.
  59. Priebe S, Wildgrube C, Muller-Oerlinghausen B: Lithium prophylaxis and expressed emotion. Br J Psychiatry 1989;154:396–399.
  60. Fountoulakis KN, Vieta E, Siamouli M, Valenti M, Magiria S, Oral T, Fresno D, Giannakopoulos P, Kaprinis GS: Treatment of bipolar disorder: a complex treatment for a multi-faceted disorder. Ann Gen Psychiatry 2007;6:27.
  61. Frank E, Kupfer DJ, Thase ME, Mallinger AG, Swartz HA, Fagiolini AM, Grochocinski V, Houck P, Scott J, Thompson W, Monk T: Two-year outcomes for interpersonal and social rhythm therapy in individuals with bipolar I disorder. Arch Gen Psychiatry 2005;62:996–1004.
  62. Lam DH, Hayward P, Watkins ER, Wright K, Sham P: Relapse prevention in patients with bipolar disorder: cognitive therapy outcome after 2 years. Am J Psychiatry 2005;162:324–329.
  63. Lam DH, Watkins ER, Hayward P, Bright J, Wright K, Kerr N, Parr-Davis G, Sham P: A randomized controlled study of cognitive therapy for relapse prevention for bipolar affective disorder: outcome of the first year. Arch Gen Psychiatry 2003;60:145–152.
  64. Reinares M, Colom F, Sanchez-Moreno J, Torrent C, Martinez-Aran A, Comes M, Goikolea JM, Benabarre A, Salamero M, Vieta E: Impact of caregiver group psychoeducation on the course and outcome of bipolar patients in remission: a randomized controlled trial. Bipolar Disord 2008;10:511–519.
  65. Weitzman A, Tal V: Bipolar Disorder (Manic-Depression). Rosh Haayin, Prolog Publishing House, 2001.
  66. Miklowitz DJ: The Bipolar Disorder Survival Guide. New York, Guilford Press, 2002.
  67. Fink DF, Kraynak J: Bipolar Disorder for Dummies. New Jersey, Wiley Publishing Inc, 2005.
  68. Schou M: Lithium Treatment of Manic-Depressive Illness, ed 3. Basel, Karger, 1986.
  69. Colom F, Vieta E: Psychoeducation Manual for Bipolar Disorder. Cambridge, Cambridge University Press, 2006.
  70. Belmaker RH, Shapiro J, Vainer E, Nemanov L, Ebstein RP, Agam G: Reduced inositol content in lymphocyte-derived cell lines from bipolar patients. Bipolar Disord 2002;4:67–69.
  71. Osher Y, Bersudsky Y, Silver H, Sela BA, Belmaker RH: Neuropsychological correlates of homocysteine levels in euthymic bipolar patients. J Affect Disord 2008;105:229–233.
  72. Shamir A, Ebstein RP, Nemanov L, Zohar A, Belmaker RH, Agam G: Inositol monophosphatase in immortalized lymphoblastoid cell lines indicates susceptibility to bipolar disorder and response to lithium therapy. Mol Psychiatry 1998;3:481–482.
  73. Lam DH, McCrone P, Wright K, Kerr N: Cost-effectiveness of relapse-prevention cognitive therapy for bipolar disorder: 30-month study. Br J Psychiatry 2005;186:500–506.
  74. Bauer MS, McBride L, Williford WO, Glick H, Kinosian B, Altshuler L, Beresford T, Kilbourne AM, Sajatovic M: Collaborative care for bipolar disorder. 1. Intervention and implementation in a randomized effectiveness trial. Psychiatr Serv 2006;57:927–936.
  75. Bauer MS, McBride L, Williford WO, Glick H, Kinosian B, Altshuler L, Beresford T, Kilbourne AM, Sajatovic M: Collaborative care for bipolar disorder. 2. Impact on clinical outcome, function, and costs. Psychiatr Serv 2006;57:937–945.
  76. Simon GE, Ludman EJ, Bauer MS, Unutzer J, Operskalski B: Long-term effectiveness and cost of a systematic care program for bipolar disorder. Arch Gen Psychiatry 2006;63:500–508.
  77. Gershon S, Angrist B, Shopsin B: Pharmacological agents as tools in psychiatric research; in Gershon ES, Belmaker RH, Kety SS, Rosenbaum M (eds): The Impact of Biology on Modern Psychiatry. New York, Plenum Press, 1977.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50